163 related articles for article (PubMed ID: 29488249)
21. PROPORTIONAL HAZARDS MODELS WITH CONTINUOUS MARKS.
Sun Y; Gilbert PB; McKeague IW
Ann Stat; 2009 Feb; 37(1):394-426. PubMed ID: 19838313
[TBL] [Abstract][Full Text] [Related]
22. Semiparametric methods for multiple exposure mismeasurement and a bivariate outcome in HIV vaccine trials.
Golm GT; Halloran ME; Longini IM
Biometrics; 1999 Mar; 55(1):94-101. PubMed ID: 11318183
[TBL] [Abstract][Full Text] [Related]
23. Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types.
Gilbert PB; Self SG; Ashby MA
Biometrics; 1998 Sep; 54(3):799-814. PubMed ID: 9750238
[TBL] [Abstract][Full Text] [Related]
24. Comparison of competing risks failure time methods and time-independent methods for assessing strain variations in vaccine protection.
Gilbert PB
Stat Med; 2000 Nov; 19(22):3065-86. PubMed ID: 11113943
[TBL] [Abstract][Full Text] [Related]
25. A mark-specific quantile regression model.
Qu L; Sun L; Sun Y
Biometrika; 2024 Mar; 111(1):255-272. PubMed ID: 38948429
[TBL] [Abstract][Full Text] [Related]
26. Augmented HIV vaccine trial design for estimating reduction in infectiousness and protective efficacy.
Datta S; Halloran ME; Longini IM
Stat Med; 1998 Jan; 17(2):185-200. PubMed ID: 9483728
[TBL] [Abstract][Full Text] [Related]
27. Incorporating founder virus information in vaccine field trials.
Follmann D; Huang CY
Biometrics; 2015 Jun; 71(2):386-96. PubMed ID: 25773491
[TBL] [Abstract][Full Text] [Related]
28. Evaluating and comparing biomarkers with respect to the area under the receiver operating characteristics curve in two-phase case-control studies.
Huang Y
Biostatistics; 2016 Jul; 17(3):499-522. PubMed ID: 26883772
[TBL] [Abstract][Full Text] [Related]
29. Tests for comparing mark-specific hazards and cumulative incidence functions.
Gilbert PB; McKeague IW; Sun Y
Lifetime Data Anal; 2004 Mar; 10(1):5-28. PubMed ID: 15130048
[TBL] [Abstract][Full Text] [Related]
30. Augmented designs to assess immune response in vaccine trials.
Follmann D
Biometrics; 2006 Dec; 62(4):1161-9. PubMed ID: 17156291
[TBL] [Abstract][Full Text] [Related]
31. HIV Vaccine Efficacy Trials: RV144 and Beyond.
Heger E; Schuetz A; Vasan S
Adv Exp Med Biol; 2018; 1075():3-30. PubMed ID: 30030787
[TBL] [Abstract][Full Text] [Related]
32. Quantile Regression for Competing Risks Data with Missing Cause of Failure.
Sun Y; Wang HJ; Gilbert PB
Stat Sin; 2012 Apr; 22(2):703-728. PubMed ID: 23950622
[TBL] [Abstract][Full Text] [Related]
33. A log rank type test in observational survival studies with stratified sampling.
Bai X; Tsiatis AA
Lifetime Data Anal; 2016 Apr; 22(2):280-98. PubMed ID: 26025499
[TBL] [Abstract][Full Text] [Related]
34. Estimation of covariate-specific time-dependent ROC curves in the presence of missing biomarkers.
Li S; Ning Y
Biometrics; 2015 Sep; 71(3):666-76. PubMed ID: 25891918
[TBL] [Abstract][Full Text] [Related]
35. Predicting Overall Vaccine Efficacy in a New Setting by Re-Calibrating Baseline Covariate and Intermediate Response Endpoint Effect Modifiers of Type-Specific Vaccine Efficacy.
Gilbert PB; Huang Y
Epidemiol Methods; 2016 Dec; 5(1):93-112. PubMed ID: 28154793
[TBL] [Abstract][Full Text] [Related]
36. Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials.
Huang Y; Zhang L; Janes H; Frahm N; Isaacs A; Kim JH; Montefiori D; McElrath MJ; Tomaras GD; Gilbert PB
Vaccine; 2017 Feb; 35(8):1184-1193. PubMed ID: 28131393
[TBL] [Abstract][Full Text] [Related]
37. Joint inferences on vaccine efficacy against infection and disease with application to the first HIV vaccine efficacy trial.
Cai T; Gilbert PB; Self SG
J Biopharm Stat; 2006; 16(4):517-38. PubMed ID: 16892911
[TBL] [Abstract][Full Text] [Related]
38. Semiparametric regression and risk prediction with competing risks data under missing cause of failure.
Bakoyannis G; Zhang Y; Yiannoutsos CT
Lifetime Data Anal; 2020 Oct; 26(4):659-684. PubMed ID: 31982977
[TBL] [Abstract][Full Text] [Related]
39. Some important issues in the planning of phase III HIV vaccine efficacy trials.
Boily MC; Mâsse BR; Desai K; Alary M; Anderson RM
Vaccine; 1999 Feb; 17(7-8):989-1004. PubMed ID: 10067708
[TBL] [Abstract][Full Text] [Related]
40. Case-only method for cause-specific hazards models with application to assessing differential vaccine efficacy by viral and host genetics.
Dai JY; Li SS; Gilbert PB
Biostatistics; 2014 Jan; 15(1):196-203. PubMed ID: 23813283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
